Stockscreener 앱 받기
59.08
0.22%
0.13
전일 마감가:
$58.95
열려 있는:
$59.67
하루 거래량:
9.39M
Relative Volume:
0.70
시가총액:
$120.31B
수익:
$48.19B
순이익/손실:
$7.06B
주가수익비율:
17.08
EPS:
3.4587
순현금흐름:
$12.85B
1주 성능:
-2.01%
1개월 성능:
-2.73%
6개월 성능:
+27.88%
1년 성능:
-1.99%
1일 변동 폭
$58.75
$60.06
1주일 범위
$58.32
$60.95
52주 변동 폭
$42.52
$62.89
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.08 | 120.31B | 48.19B | 7.06B | 12.85B | 3.4587 |
|
LLY
Lilly Eli Co
|
985.08 | 879.67B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
241.52 | 582.04B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
219.68 | 388.43B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
189.90 | 294.50B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
153.44 | 292.79B | 54.72B | 14.02B | 15.32B | 7.1855 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
1 ETF That Could Turn $100 Per Month Into $67,380 - The Motley Fool
Bristol Myers Squibb to make immune cell cancer therapies in Japan - Nikkei Asia
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors - ChartMill
Bristol Myers Squibb Company $BMY Shares Sold by Employees Retirement System of Texas - MarketBeat
Colgate-Palmolive Elects Christopher Boerner, Ph.D. to Board of Directors - citybiz
Colgate-Palmolive raises dividend, adds Bristol Myers CEO to board By Investing.com - Investing.com India
Is Bristol Myers' Deep Pipeline the Key to Future Growth? - The Globe and Mail
Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry - Insider Monkey
UBS Boosts Bristol-Myers Squibb (BMY) Price Target as Milvexian Data Looms - Finviz
LGT Fund Management Co Ltd. Has $372,000 Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Readies New Growth Drivers In Immunology And Cancer - simplywall.st
Bristol Myers Squibb (NYSE:BMY) Boosts Research Strengthening S&P 500 Index Momentum - Kalkine Media
BMY Wins FDA Nod to Expand Sotyktu Label for Psoriatic Arthritis - Finviz
Bristol Myers Squibb reports positive phase 3 trial results - Investing.com
Bristol's cancer treatment meets main goal in late-stage trial - AOL.com
Bristol's drug enhances survival rates in late-stage blood cancer trial - Reuters
New Bristol Myers pill delays myeloma progression in key late-stage trial - Stock Titan
Blair William & Co. IL Reduces Bristol Myers Squibb Stake - National Today
Oral Mucositis Market Set to Boom Through 2033 | Bristol-Myers Squibb • Pfizer Inc. • Novartis AG - openPR.com
Pitcairn Co. Sells 20,260 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Blair William & Co. IL Lowers Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
B. Metzler seel. Sohn & Co. AG Has $5.05 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers (BMY) Gains FDA Approval for Sotyktu in Psoriatic Arthritis Treatment - GuruFocus
Munich Reinsurance Co Stock Corp in Munich Takes $2.78 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Has $43.66 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb's Sotyktu Approved for Psoriatic Arthritis Treatment - Intellectia AI
Bristol Myers Wins FDA Approval for Sotyktu for Psoriatic Arthritis - Benzinga
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MSN
Bristol Myers wins FDA nod to expand Sotyktu label (BMY:NYSE) - Seeking Alpha
Painful psoriatic arthritis gets new oral option with FDA Sotyktu approval - Stock Titan
UBS raises Bristol-Myers Squibb stock price target on pipeline outlook - Investing.com
Why Bristol-Myers Squibb Remains a Top Healthcare Dividend Stock Pick - Tokenist
IFG Advisory LLC Acquires New Position in Bristol Myers Squibb Company - National Today
Edgar Lomax Co. VA Reduces Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Is It Too Late To Consider Bristol Myers Squibb (BMY) After Recent Share Price Strength? - simplywall.st
Bristol-Myers Squibb Announces Cash Tender Offer For Up to $750 Million Aggregate Principal Amount of its Outstanding Debt Se... - mx.advfn.com
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? - TradingView
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Assessing Bristol Myers Squibb (BMY) Valuation After Recent Share Price Momentum And 2024 Results - simplywall.st
Bristol Myers Squibb Awaits FDA Verdict On Sotyktu In Psoriatic Arthritis - RTTNews
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
How New Oncology Wins and a Fresh Dividend At Bristol Myers Squibb (BMY) Have Changed Its Investment Story - simplywall.st
Wealthedge Investment Advisors Boosts Bristol Myers Squibb Holdings - National Today
Patient Advocate Foundation Announces $1 Million Donation from Bristol Myers Squibb Foundation - Patient Advocate Foundation
Bristol Myers Squibb declares $0.63 quarterly dividend - Investing.com
APG Asset Management Trims Bristol Myers Squibb Stake - National Today
Elo Mutual Pension Insurance Co Increases Bristol Myers Squibb Position - National Today
Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend of $0.63/Share - GuruFocus
Bristol Myers Squibb at TD Cowen Conference: Strategic Growth Amid Challenges - Investing.com
BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock? - TradingView
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.04%
자본화:
|
볼륨(24시간):